• Company
  • News
  • Investors
  • Contacts
  • Careers
polypeptide-logopolypeptide-logologo-mobilepolypeptide-logo
  • Services
    • GMP Compliance
    • Pre-GMP development
    • Production
    • Quality Assurance
    • Quality control
    • Regulatory Support
  • Commercial Manufacturing
    • Commercial products at PolyPeptide
    • Late stage development
    • Process development and optimization
    • Capacity and Capabilities
  • Custom R&D
    • Custom Research Grade Peptides
    • Radiolabeled peptide
  • Generic peptides
  • Oligos
  • Services
    • GMP Compliance
    • Pre-GMP development
    • Production
    • Quality Assurance
    • Quality control
    • Regulatory Support
  • Commercial Manufacturing
    • Commercial products at PolyPeptide
    • Late stage development
    • Process development and optimization
    • Capacity and Capabilities
  • Custom R&D
    • Custom Research Grade Peptides
    • Radiolabeled peptide
  • Generic peptides
  • Oligos
✕
  • Home
  • News
  • Expert views
  • Minimizing HCN in DIC/Oxyma-Mediated Amide Bond-Forming Reactions

Minimizing HCN in DIC/Oxyma-Mediated Amide Bond-Forming Reactions

15 June 2020
Expert views

Aiming at advancing protocols for safer, environmentally sensible peptide synthesis we report our findings with regard to the occurrence of hydrogen cyanide (HCN, prussic acid) in amide bond-forming reactions mediated by diisopropylcarbodiimide (DIC) and ethyl (hydroxyimino)cyanoacetate (Oxyma).[…]

Aiming at advancing protocols for safer, environmentally sensible peptide synthesis we report our findings with regard to the occurrence of hydrogen cyanide (HCN, prussic acid) in amide bond-forming reactions mediated by diisopropylcarbodiimide (DIC) and ethyl (hydroxyimino)cyanoacetate (Oxyma). We determined that HCN is always formed in amide bond-forming reactions on solid support in N,N-dimethylformamide (DMF) when DIC/Oxyma is employed.

Marion Erny, Marika Lundqvist, Jon H. Rasmussen, Olivier Ludemann-Hombourger, Frédéric Bihel, and Jan Pawlas, Organic Process Research & Development, https://doi.org/10.1021/acs.oprd.0c00227

June 15 2020

Read more

Back to news

Related posts

2 April 2025

Expanding the Reach of Sustainable Solid-Phase Peptide Synthesis


Read more
20 March 2025

Impurities in Peptide Drug Substance and Challenges Faced during Registration (in US, EU, Brazil and China Markets) and Commercial Phase


Read more
13 November 2024

Peptide Manufacturing: Rethinking the Technology Platform for Large Scale Demand


Read more

Polypeptide Group

INFO

COMPANY
LEADERSHIP
CONTACTS
CAREERS

NEWS

LATEST NEWS
SIGN UP FOR NEWS
EVENTS

SOCIALS

LINKEDIN
YOUTUBE
© Confidentiality 2025 PolyPeptide Group • Cookie Policy • Sitemap • Privacy policy
    • Company
    • News
    • Investors
    • Contacts
    • Careers